Which medications in the drug class Colony-stimulating Factors are used in the treatment of Pediatric Neuroblastoma?

Updated: Oct 09, 2017
  • Author: Norman J Lacayo, MD; Chief Editor: Max J Coppes, MD, PhD, MBA  more...
  • Print

Colony-stimulating Factors

These agents act as a hematopoietic growth factor that stimulates the development of granulocytes. They are used to treat or prevent neutropenia when receiving myelosuppressive cancer chemotherapy and to reduce the period of neutropenia associated with bone marrow transplantation. They are also used to mobilize autologous peripheral blood progenitor cells for bone marrow transplantation and in the management of chronic neutropenia.

A multicenter, randomized trial by Ladenstein et al observed pediatric patients (n=239) with neuroblastoma in 16 countries. [25] Patients who were given primary prophylactic G-CSF had significantly fewer febrile neutropenic episodes, days with fever, hospital days, and antibiotic days compared with those who received symptom-triggered G-CSF. Other toxicities were significantly reduced as well including infections, fever, severe leukopenia, neutropenia, mucositis, nausea/vomiting, constipation, and weight loss.

Filgrastim (G-CSF, Neupogen)

Promotes growth and differentiation of myeloid progenitor cells. May improve survival and function of granulocytes. In the posttransplant setting, administer until marrow recovery with absolute neutrophil count >10,000.

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!